JP7035044B2 - α４β７インテグリンを標的とする環状ペプチド多量体 - Google Patents

α４β７インテグリンを標的とする環状ペプチド多量体 Download PDF

Info

Publication number
JP7035044B2
JP7035044B2 JP2019524203A JP2019524203A JP7035044B2 JP 7035044 B2 JP7035044 B2 JP 7035044B2 JP 2019524203 A JP2019524203 A JP 2019524203A JP 2019524203 A JP2019524203 A JP 2019524203A JP 7035044 B2 JP7035044 B2 JP 7035044B2
Authority
JP
Japan
Prior art keywords
disease
homodimer
acid
integrin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504080A5 (https=
JP2020504080A (ja
Inventor
モルシェド，マンズール，エム．
チャッカ，サイ，クマル
ヒッキー，ジェニファー，エル．
ペレス バスケス，マニュエル
ラフトン，アンドリュー
ポール カファル，アダム
ビー． パテル，ナレンドラクマール
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2020504080A publication Critical patent/JP2020504080A/ja
Publication of JP2020504080A5 publication Critical patent/JP2020504080A5/ja
Priority to JP2022032190A priority Critical patent/JP7429726B2/ja
Application granted granted Critical
Publication of JP7035044B2 publication Critical patent/JP7035044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2019524203A 2016-11-11 2017-11-10 α４β７インテグリンを標的とする環状ペプチド多量体 Active JP7035044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022032190A JP7429726B2 (ja) 2016-11-11 2022-03-02 α４β７インテグリンを標的とする環状ペプチド多量体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421117P 2016-11-11 2016-11-11
US62/421,117 2016-11-11
PCT/CA2017/000244 WO2018085921A1 (en) 2016-11-11 2017-11-10 CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022032190A Division JP7429726B2 (ja) 2016-11-11 2022-03-02 α４β７インテグリンを標的とする環状ペプチド多量体

Publications (3)

Publication Number Publication Date
JP2020504080A JP2020504080A (ja) 2020-02-06
JP2020504080A5 JP2020504080A5 (https=) 2020-12-17
JP7035044B2 true JP7035044B2 (ja) 2022-03-14

Family

ID=62110102

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524203A Active JP7035044B2 (ja) 2016-11-11 2017-11-10 α４β７インテグリンを標的とする環状ペプチド多量体
JP2022032190A Active JP7429726B2 (ja) 2016-11-11 2022-03-02 α４β７インテグリンを標的とする環状ペプチド多量体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022032190A Active JP7429726B2 (ja) 2016-11-11 2022-03-02 α４β７インテグリンを標的とする環状ペプチド多量体

Country Status (8)

Country Link
US (3) US11111273B2 (https=)
EP (2) EP3939989A1 (https=)
JP (2) JP7035044B2 (https=)
CN (1) CN110088121A (https=)
CA (1) CA3042576A1 (https=)
DK (1) DK3538542T3 (https=)
ES (1) ES2884107T3 (https=)
WO (1) WO2018085921A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
KR20230079464A (ko) 2017-05-10 2023-06-07 질랜드 파마 에이/에스 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230117920A1 (en) * 2019-12-27 2023-04-20 The University Of Tokyo Library Construction Method, Cyclic Peptide, FXIIa Binder and IFNGR1 Binder
JP2021106565A (ja) * 2019-12-27 2021-07-29 国立大学法人 東京大学 ライブラリーの製造方法、環状ペプチド、ＦＸＩＩａ結合剤、及びＩＦＮＧＲ１結合剤
EP4172177A1 (en) * 2020-06-29 2023-05-03 Zealand Pharma A/S Compounds targeting alpha4-beta7 integrin
US11957761B2 (en) 2021-12-20 2024-04-16 Zealand Pharma A/S Compounds having α4β7 integrin inhibition activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219113A1 (de) 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
ZA906188B (en) 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
US5705481A (en) 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
IL109615A (en) 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
WO1996000581A1 (en) 1994-06-29 1996-01-11 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5696084A (en) 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
US6667407B2 (en) 2002-05-03 2003-12-23 Bayer Polymers Llc Process of making polyaziridines
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US8143375B2 (en) 2006-10-20 2012-03-27 The Governing Council Of The University Of Toronto Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
EP2291390B1 (en) 2008-05-22 2014-11-05 Centre National de la Recherche Scientifique (CNRS) New optically pure compounds for improved therapeutic efficiency
AU2010225426B2 (en) * 2009-03-16 2015-09-03 The Governing Council Of The University Of Toronto Cyclic amino acid molecules and methods of preparing the same
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
WO2012113803A1 (en) 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
BR112014016736A8 (pt) * 2012-01-27 2017-07-04 Hoffmann La Roche composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
JP6152093B2 (ja) * 2012-04-24 2017-06-21 Ｅａファーマ株式会社 スルホンアミド誘導体及びその医薬用途
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
KR20170108936A (ko) * 2014-10-01 2017-09-27 프로타고니스트 테라퓨틱스, 인코포레이티드 신규한 α4β7 펩타이드 단량체 및 이량체 길항제
US11046695B2 (en) 2015-11-11 2021-06-29 Zealand Pharma A/S Fragment synthesis of substituted cyclic peptides
US11111273B2 (en) * 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，Vol. 44，2001年，P. 2586-2592
JOURNAL OF PEPTIDE SCIENCE，2000年，Vol. 6，P. 321-341

Also Published As

Publication number Publication date
ES2884107T3 (es) 2021-12-10
DK3538542T3 (da) 2021-10-11
JP2020504080A (ja) 2020-02-06
CN110088121A (zh) 2019-08-02
EP3538542A4 (en) 2020-08-26
CA3042576A1 (en) 2018-05-17
JP2022078188A (ja) 2022-05-24
US11713338B2 (en) 2023-08-01
US20200216501A1 (en) 2020-07-09
JP7429726B2 (ja) 2024-02-08
US11111273B2 (en) 2021-09-07
EP3939989A1 (en) 2022-01-19
EP3538542A1 (en) 2019-09-18
WO2018085921A1 (en) 2018-05-17
US20230406884A1 (en) 2023-12-21
US12077611B2 (en) 2024-09-03
US20210324007A1 (en) 2021-10-21
EP3538542B1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
JP7035044B2 (ja) α４β７インテグリンを標的とする環状ペプチド多量体
CN109071602B (zh) 靶向α4β7整联蛋白的环肽
JP7274425B2 (ja) α４β７インテグリンを標的とするホモデチック環状ペプチド
SK63498A3 (en) Novel macrocyclic compounds as metalloprotease inhibitors
TWI258469B (en) Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
JP2020500907A (ja) 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
JP2009519945A (ja) 非天然アミノ酸およびそれらのニューロテンシンアナログ
CN107602450B (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用
AU2022420665A1 (en) Compounds
RU2773443C2 (ru) ГОМОДЕТНЫЕ ЦИКЛИЧЕСКИЕ ПЕПТИДЫ, ЦЕЛЕНАПРАВЛЕННО ВОЗДЕЙСТВУЮЩИЕ НА ИНТЕГРИН α4β7
HK40067055A (en) Cyclic peptides multimers targeting alpha 4beta 7 integrin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201104

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220302

R150 Certificate of patent or registration of utility model

Ref document number: 7035044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250